• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: November 6-10


ICYMI, this week we had articles about a proposed ban of formaldehyde in hair relaxers, TAK-279 for psoriatic arthritis, and updated atopic dermatitis guidelines from AAD.

Mohs Surgery Improves Rates of Nodal Metastasis and Disease Specific Death in cSCC

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

The Cutaneous Connection: Pearls for Atopic Dermatitis in College-Aged Patients

In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management.

Meta-Analysis Finds Chinese Patent Medicines May Be Efficacious, Suitable Interventions for Vitiligo

Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.

Proposed FDA Ban of Formaldehyde in Hair Relaxers: What Comes Next?

Christopher Bunick, MD, PhD, and David Light, CEO of Valisure, weigh in on the proposed formaldehyde ban.

Older, Middle-Aged Adults With Atopic Dermatitis Face an Increased Risk of Cognitive Dysfunction

Study authors urge clinicians to screen adult patients with AD for cognitive dysfunction.

Combined With NB-UVB Therapy, Topical Vitamin D May Enhance Therapeutic Outcomes of Vitiligo

Incorporating vitamin D may mitigate adverse effects of corticosteroids, though more research is needed to discover the best methods for topical administration in vitiligo.

POLL: What 2023 NP & PA Conference Has Been Your Favorite?

Click here to answer this week's NP & PA poll.

Dermatologists Play Crucial Role in Support and Inclusivity of Transgender and Gender-Diverse Patients

Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.

TAK-279 Shows Significant Efficacy in Phase 2b Psoriatic Arthritis Study

Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.

FDA Accepts sBLA for Interchangeability Designation for Adalimumab-bwwd

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

ASDS: Review of Lasers and Light-Based Therapies for Acne

New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.

First US Patient Dosed in Phase III Trial With Vilobelimab For Pyoderma Gangrenosum

Vilobelimab has received Fast Track and Orphan Drug designations from the FDA, as well as an Orphan Drug designation from the European Medicines Agency for the treatment of PG.

Evaluating the Efficacy and Safety of Organic Acids in Chemical Peels for Acne

Despite how widely used these acids often are, there is still a lack of general consensus for which are the most effective in patients with acne-prone skin.

Pointers With Portela: Retinol Alternatives

In this week’s Pointers With Portela, the 208SkinDoc discusses the best retinol alternatives in 2023.

AD Management in a New Lifestyle Transition

New lifestyle transitions can affect a patient's treatment adherence and support network. How would you help this new college student?

Shawn Kwatra, MD: Nemolizumab Modulates Neuroimmune and Epithelial Dysregulation in Patients with Prurigo Nodularis

Kwatra discussed his research team’s findings published in JAMA Dermatology.

Updated AAD Guidelines for the Management of AD with Phototherapy and Systemic Therapies

The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.

Highlights From 2023 NP & PA Conferences: Part 1

Catch up on the best highlights from Fall Clinical for PAs & NPs, SDPA Summer, and Maui Derm NP + PA Summer.

Evaluating Stress Levels in AD Treatment Plans

The case of a 45-year-old woman with AD challenges clinicians on how to consider stress as an exacerbating factor in a treatment-resistant case.

Treatment Advances, Insights Expected at the 2023 ACAAI Annual Scientific Meeting

New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

POLL: What Treatment Option Do You Most Commonly Use for Patients With Hyperhidrosis?

Click here to answer this week's poll for hyperhidrosis awareness month.

Remibrutinib Improves Chronic Spontaneous Urticaria Symptoms at Week 2

Data from Novartis will be presented at the 2023 American College of Allergy, Asthma, and Immunology Scientific Meeting.

Patients With Mild Psoriasis Experience Less Favorable Status at Diagnosis and First Line of Treatment

Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.

Experts Excited by Advancements in Vitiligo Treatment

Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.

National Rosacea Society Awards 2023 Grants for Research

Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.

Addressing Mental Health Issues in Patients with Atopic Dermatitis

A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.

Jay A. Lieberman, MD, FACAAI: Clinical Pearls and Hands-On Educational Opportunities at ACAAI Annual Meeting

Program Chair Jay A. Lieberman, MD, provides a glimpse into the clinical pearls and dermatological educational opportunities presented at the ACAAI 2023 Annual Scientific Meeting.

Highlights From 2023 NP & PA Conferences: Part 2

Catch up on the best highlights from Maui Derm NP + PA Fall, Inflammatory Disease Summit, and SDPA Fall.

Nemolizumab Significantly Reduces Itch and Improves DLQI in Patients With Prurigo Nodularis

Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.